P
ANIP icon

Pitcairn’s ANI Pharmaceuticals ANIP Stock Holding History

Pitcairn’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,764
Closed -$293K – 445
2019
Q4 		$293K Buy
4,764
+753
+19% +$49.9K 0.03% 406
2019
Q3 		$292K Sell
4,011
-243
-6% -$18.2K 0.03% 392
2019
Q2 		$350K Buy
4,254
+27
+0.6% +$1.92K 0.04% 336
2019
Q1 		$299K Buy
+4,227
New +$249K 0.03% 358
2018
Q4 		– Sell
-3,800
Closed -$214K – 455
2018
Q3 		$214K Sell
3,800
-297
-7% -$18.2K 0.02% 503
2018
Q2 		$274K Buy
4,097
+76
+2% +$4.75K 0.03% 436
2018
Q1 		$234K Buy
+4,021
New +$255K 0.02% 464

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pitcairn's ANIP Position: Q1 2020 in Review

Pitcairn sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 4,764 shares — an estimated $293K sold.

Pitcairn first reported a position in ANIP in Q1 2018 and held it in 7 quarters. The position peaked at $350K in Q2 2019. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

  • Pitcairn reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Pitcairn sold 4,764 ANI Pharmaceuticals shares in Q1 2020, an estimated $293K.
  • Pitcairn first reported a position in ANI Pharmaceuticals in Q1 2018 and held it in 7 quarters.
  • Pitcairn's ANI Pharmaceuticals position peaked at $350K in Q2 2019.
  • 140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Pitcairn's 13F filing for Q1 2020, filed 13 May 2020.